Login to Your Account

Renovis Plummets On Phase III Miss With Stroke Drug, NXY-059

By Jennifer Boggs

Friday, October 27, 2006
AstraZeneca plc opted to discontinue development of the stroke drug NXY-059 after the product missed its primary endpoint in a Phase III trial, sending shares of Renovis Inc., the drug's licensor, plunging more than 70 percent Thursday. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription